ライフサイエンスコーパス: MMPI

1 MMPI-2 results were of questionable validity because of

2 nnesota Multiphasic Personality Inventory 2 (MMPI-2) was administered to 19 LNP subjects self-describ

3 udes Test-26, Eating Disorder Inventory, and MMPI-II, was similar for both patient groups.

4 show variability in rats and mice to LPS and MMPIs, which most likely is based on genetic make-up.

5 he first report to show a positive effect by MMPIs on chronic relapsing EAE, its central nervous syst

6 Is, we discovered a new class of fluorinated MMPIs with a triazole-substituted hydroxamate substructu

7 umulated data, it is recommended that future MMPI trials focus on: (1) patients with early stage canc

8 Investigations with hydroxamate MMPIs, including those designed for deep pocket MMPs, al

9 ial scarring were significantly decreased in MMPI-treated mice with chronic relapsing EAE, as was cen

10 r MMP inducer; Prinomastat [a MMP inhibitor (MMPI)] significantly decreased cyclic strain-induced pro

11 Matrix metalloproteinase inhibitors (MMPIs) reduce blood-brain barrier (BBB) disruption and p

12 olidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated.

13 e-based matrix metalloproteinase inhibitors (MMPIs).

14 cked by matrix metalloproteinase inhibitors (MMPIs).

15 alized by using radiolabeled MMP inhibitors (MMPIs) as positron emission tomography (PET) imaging age

16 tablished using radiolabeled MMP inhibitors (MMPIs) as tracers for the detection of activated MMPs by

17 l evolution of the synthetic MMP inhibitors (MMPIs) is also examined, with the discussion encompassin

18 IMP-2, and several synthetic MMP inhibitors (MMPIs) on the shedding of both tumor necrosis factor alp

19 Consequently, MMP inhibitors (MMPIs) radiolabeled with positron emitting nuclides (e.g

20 ell tolerated, orally active MMP inhibitors (MMPIs) which demonstrated efficacy in mouse cancer model

21 f new potent mercaptosulfide MMP inhibitors (MMPIs) with Leu or homophenylalanine (Homophe) side chai

22 Minnesota Multiphasic Personality Inventory (MMPI-2) in 1986.

23 Minnesota Multiphasic Personality Inventory (MMPI-2) Type A Scale.

24 nd unlabeled derivatives of the nonselective MMPIs, we discovered a new class of fluorinated MMPIs wi

25 These novel MMPIs are characterized by an increased hydrophilicity c

26 ciated with determining clinical efficacy of MMPIs and other novel therapeutic agents.

27 In retrospect, the failure of MMPIs to alter disease progression in metastatic cancer

28 damage would be more useful for screening of MMPIs.

29 mportant clues that could guide selection of MMPIs in treatment of neurological diseases.

30 inued their ongoing Phase III drug trials of MMPIs in advanced cancer.

31 ents with early stage cancer; (2) the use of MMPIs along with chemotherapy; (3) the measurement of MM

32 Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compoun

33 Pharmacological MMPIs should be considered in the pursuit of therapeutic

34 In this study, we show that a potent MMPI was clinically effective in an animal model for MS,

35 Results reveal legume protein MMPIs as novel metalloproteinase inhibitors with possibl

36 Descriptions of individual patients resemble MMPI profiles, based on the degree of match between the

37 s in a delayed opening of the BBB, to screen MMPIs to identify therapeutic agents.

38 Initially, we tested three broad-spectrum MMPIs in the rat, BB-1101, BB-94, and BB-2293, and a MMP

39 ethylprednisolone and several broad-spectrum MMPIs, including BB-1101, was ineffective in the C57/BL6

40 he initially discovered triazole-substituted MMPIs, an additional CH2-group between the backbone of t

41 Triazole-substituted MMPIs, discovered by our group, are highly potent inhibi

42 -dependent manner by the following synthetic MMPIs: batimastat and marimastat (BB-94 and BB-2516, res

43 or the pharmacological activity of synthetic MMPIs.

44 The synthetic MMPIs and TIMP-2, but not TIMP-1, also caused a dose-dep

45 equired with low molecular weight, synthetic MMPIs but at concentrations greater than those required

46 This study suggests that MMPIs, protein sequence analyses, and molecular modeling

47 The MMPI-2 showed a high score on the "lie" validity scale f

48 The MMPI-2 Type A Scale predicts CHD incidence.

49 The MMPI/MMPI-2 remains the most popular instrument for both

50 free of diagnosed CHD in 1986 completed the MMPI-2 Type A Scale.

51 egorized according to their responses to the MMPI-2 Anger Content Scale, which measures the degree to

52 g patients who are more likely to respond to MMPI therapy; and (4) identification of biomarkers that

53 bstituted hydroxamates, the inverse triazole MMPIs are excellent inhibitors with promising in vivo pr

54 cterial meningitis respond to treatment with MMPIs.

55 pared the response to LPS and treatment with MMPIs.